Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 14, 2013
Event: Entry into a Material Definitive Agreement regarding a public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key metrics related to the transaction include:
- Shares Issued: 29,411,765 shares of common stock.
- Public Offering Price: $1.70 per share.
- Underwriter Purchase Price: $1.581 per share.
- Expected Net Proceeds: Approximately $45.6 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 4,411,765 shares.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transaction report, not a periodic financial statement.
Material Changes
The primary material change is the execution of an underwriting agreement with Jefferies LLC to raise capital. This represents a significant increase in the company's equity capital base upon closing, expected on or about March 20, 2013.
Guidance, Outlook, and Risks
Management Commentary: The company priced the offering on March 15, 2013, pursuant to a shelf registration statement (Form S-3) declared effective on February 5, 2013.
Risks and Contingencies: The closing of the offering is subject to customary closing conditions. The Underwriting Agreement includes standard representations, warranties, covenants, and indemnification obligations.
Investor Verification Checklist
- Verify the final closing date of the offering (expected March 20, 2013).
- Confirm whether the underwriters exercised the option to purchase the additional 4,411,765 shares.
- Review the final net proceeds received after all offering expenses are deducted.
- Check subsequent filings for the updated share count and dilution impact on existing shareholders.